Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth

Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth

Abstract Background Patients with advanced colorectal cancer (CRC) have a poor prognosis. Combinations of immunotherapies and anti-angiogenic agents are currently being evaluated in clinical trials. In this study, the multikinase inhibitor regorafenib (REG) was combined with an anti-programmed cell...

Full description

Bibliographic Details
Main Authors: Dennis Doleschel, Sabine Hoff, Susanne Koletnik, Anne Rix, Dieter Zopf, Fabian Kiessling, Wiltrud Lederle
Format: Article
Language:English
Published: BMC 2021-09-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Colorectal cancer
Metastasis
Anti-PD1 antibody
Regorafenib
Preclinical
Macrophage polarization
Online Access:https://doi.org/10.1186/s13046-021-02043-0

Internet

https://doi.org/10.1186/s13046-021-02043-0

Similar Items